FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 707 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Stopping neuropathy: One of chemotherapy’s most challenging side effects May 22, 2023 FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable Hepatocellular Carcinoma October 27, 2022 LGBTQ+ Voices: Listening to Sexual and Gender Minority People Affected by... May 1, 2024 Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or... February 19, 2026 Load more HOT NEWS Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14... Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App Cancer Research UK honours Her Majesty The Queen, the charity’s Patron What to Know About Cancer Clinical Trial Matching Programs
